Famed boot manufacturer Dr. Martens anticipates a significant financial impact from US tariffs this year. The company, known for its iconic yellow-stitched boots, foresees a multimillion-pound hit due to increased import duties on footwear made in Vietnam, a move prompted by the trade tensions initiated by US President Donald Trump.
Dr. Martens, which has transitioned its production base from China to mitigate US import tariffs, is preparing for a substantial impact on full-year profits. Despite this challenge, the company remains optimistic about meeting its underlying pre-tax profit forecasts for the year, ranging from £53 million to £60 million.
Following a stock market announcement, Dr. Martens observed a sharp decline in its share price, dropping more than 10% during early trading. The company outlined plans to offset the tariff costs starting next year through cost control measures, adjusting product sourcing strategies, and revising pricing policies in the US market.
In its latest financial report, Dr. Martens reported a decrease in losses to £11 million for the six-month period ending September 28, with a modest sales increase of 0.8% to £327.3 million in the first half of the year. The brand’s CEO, Ije Nwokorie, expressed confidence in the company’s performance, highlighting the positive reception of new product launches.
Despite ongoing uncertainties in the market, Dr. Martens’ strategic efforts to enhance profitability are seen as incremental progress by industry experts. While the company’s financial results show signs of improvement, investor response has been lukewarm, reflected in the initial trading decline of its share price.
